Financhill
Sell
5

PRCT Quote, Financials, Valuation and Earnings

Last price:
$80.60
Seasonality move :
4.99%
Day range:
$79.41 - $82.28
52-week range:
$39.48 - $103.81
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
20.84x
P/B ratio:
18.21x
Volume:
1.2M
Avg. volume:
623.6K
1-year change:
102.93%
Market cap:
$4.4B
Revenue:
$136.2M
EPS (TTM):
-$1.95

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
PRCT
PROCEPT BioRobotics
$53.2M -$0.49 53.23% -37.41% $102.75
BSX
Boston Scientific
$4B $0.59 18.39% 92.99% $99.00
CATX
Perspective Therapeutics
$237.9K -$0.20 -- -70.12% --
ISRG
Intuitive Surgical
$2B $1.64 14.07% 3.69% $556.42
RXST
RxSight
$35.1M -$0.07 40.98% -79.43% $58.00
TFX
Teleflex
$767.8M $3.39 5.09% 487.41% $238.68
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
PRCT
PROCEPT BioRobotics
$81.17 $102.75 $4.4B -- $0.00 0% 20.84x
BSX
Boston Scientific
$88.95 $99.00 $131.1B 73.51x $0.00 0% 8.29x
CATX
Perspective Therapeutics
$2.85 -- $192.6M -- $0.00 0% 15.39x
ISRG
Intuitive Surgical
$524.43 $556.42 $186.8B 84.31x $0.00 0% 24.04x
RXST
RxSight
$33.67 $58.00 $1.4B -- $0.00 0% 9.91x
TFX
Teleflex
$178.16 $238.68 $8.3B 35.42x $0.34 0.76% 2.78x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
PRCT
PROCEPT BioRobotics
17.58% 0.117 1.23% 4.95x
BSX
Boston Scientific
34.45% 0.299 8.79% 0.85x
CATX
Perspective Therapeutics
-- -5.312 -- --
ISRG
Intuitive Surgical
-- 1.253 -- 3.29x
RXST
RxSight
-- 1.542 -- 11.60x
TFX
Teleflex
28.18% 1.089 15.31% 1.15x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
PRCT
PROCEPT BioRobotics
$36.9M -$22.4M -31.39% -37.42% -33.98% -$19M
BSX
Boston Scientific
$2.9B $718M 5.95% 8.91% 17.77% $698M
CATX
Perspective Therapeutics
-- -$18.6M -- -- -- -$26.3M
ISRG
Intuitive Surgical
$1.4B $577.3M 15.9% 15.9% 28.33% $458.6M
RXST
RxSight
$25.2M -$9.2M -14.78% -14.78% -17.9% -$453K
TFX
Teleflex
$430.2M $144.2M 3.78% 5.32% 19.83% $209.8M

PROCEPT BioRobotics vs. Competitors

  • Which has Higher Returns PRCT or BSX?

    Boston Scientific has a net margin of -35.93% compared to PROCEPT BioRobotics's net margin of 11.12%. PROCEPT BioRobotics's return on equity of -37.42% beat Boston Scientific's return on equity of 8.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRCT
    PROCEPT BioRobotics
    63.24% -$0.40 $292.7M
    BSX
    Boston Scientific
    68.83% $0.32 $31.8B
  • What do Analysts Say About PRCT or BSX?

    PROCEPT BioRobotics has a consensus price target of $102.75, signalling upside risk potential of 26.59%. On the other hand Boston Scientific has an analysts' consensus of $99.00 which suggests that it could grow by 11.3%. Given that PROCEPT BioRobotics has higher upside potential than Boston Scientific, analysts believe PROCEPT BioRobotics is more attractive than Boston Scientific.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRCT
    PROCEPT BioRobotics
    6 2 0
    BSX
    Boston Scientific
    20 5 0
  • Is PRCT or BSX More Risky?

    PROCEPT BioRobotics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.802, suggesting its less volatile than the S&P 500 by 19.799%.

  • Which is a Better Dividend Stock PRCT or BSX?

    PROCEPT BioRobotics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PROCEPT BioRobotics pays -- of its earnings as a dividend. Boston Scientific pays out 1.76% of its earnings as a dividend. Boston Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios PRCT or BSX?

    PROCEPT BioRobotics quarterly revenues are $58.4M, which are smaller than Boston Scientific quarterly revenues of $4.2B. PROCEPT BioRobotics's net income of -$21M is lower than Boston Scientific's net income of $468M. Notably, PROCEPT BioRobotics's price-to-earnings ratio is -- while Boston Scientific's PE ratio is 73.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PROCEPT BioRobotics is 20.84x versus 8.29x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRCT
    PROCEPT BioRobotics
    20.84x -- $58.4M -$21M
    BSX
    Boston Scientific
    8.29x 73.51x $4.2B $468M
  • Which has Higher Returns PRCT or CATX?

    Perspective Therapeutics has a net margin of -35.93% compared to PROCEPT BioRobotics's net margin of --. PROCEPT BioRobotics's return on equity of -37.42% beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    PRCT
    PROCEPT BioRobotics
    63.24% -$0.40 $292.7M
    CATX
    Perspective Therapeutics
    -- -$0.21 --
  • What do Analysts Say About PRCT or CATX?

    PROCEPT BioRobotics has a consensus price target of $102.75, signalling upside risk potential of 26.59%. On the other hand Perspective Therapeutics has an analysts' consensus of -- which suggests that it could grow by 466.67%. Given that Perspective Therapeutics has higher upside potential than PROCEPT BioRobotics, analysts believe Perspective Therapeutics is more attractive than PROCEPT BioRobotics.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRCT
    PROCEPT BioRobotics
    6 2 0
    CATX
    Perspective Therapeutics
    0 0 0
  • Is PRCT or CATX More Risky?

    PROCEPT BioRobotics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

  • Which is a Better Dividend Stock PRCT or CATX?

    PROCEPT BioRobotics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PROCEPT BioRobotics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRCT or CATX?

    PROCEPT BioRobotics quarterly revenues are $58.4M, which are larger than Perspective Therapeutics quarterly revenues of --. PROCEPT BioRobotics's net income of -$21M is lower than Perspective Therapeutics's net income of -$15.1M. Notably, PROCEPT BioRobotics's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PROCEPT BioRobotics is 20.84x versus 15.39x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRCT
    PROCEPT BioRobotics
    20.84x -- $58.4M -$21M
    CATX
    Perspective Therapeutics
    15.39x -- -- -$15.1M
  • Which has Higher Returns PRCT or ISRG?

    Intuitive Surgical has a net margin of -35.93% compared to PROCEPT BioRobotics's net margin of 27.73%. PROCEPT BioRobotics's return on equity of -37.42% beat Intuitive Surgical's return on equity of 15.9%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRCT
    PROCEPT BioRobotics
    63.24% -$0.40 $292.7M
    ISRG
    Intuitive Surgical
    67.41% $1.56 $15.7B
  • What do Analysts Say About PRCT or ISRG?

    PROCEPT BioRobotics has a consensus price target of $102.75, signalling upside risk potential of 26.59%. On the other hand Intuitive Surgical has an analysts' consensus of $556.42 which suggests that it could grow by 6.1%. Given that PROCEPT BioRobotics has higher upside potential than Intuitive Surgical, analysts believe PROCEPT BioRobotics is more attractive than Intuitive Surgical.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRCT
    PROCEPT BioRobotics
    6 2 0
    ISRG
    Intuitive Surgical
    14 8 1
  • Is PRCT or ISRG More Risky?

    PROCEPT BioRobotics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.383, suggesting its more volatile than the S&P 500 by 38.272%.

  • Which is a Better Dividend Stock PRCT or ISRG?

    PROCEPT BioRobotics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PROCEPT BioRobotics pays -- of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRCT or ISRG?

    PROCEPT BioRobotics quarterly revenues are $58.4M, which are smaller than Intuitive Surgical quarterly revenues of $2B. PROCEPT BioRobotics's net income of -$21M is lower than Intuitive Surgical's net income of $565.1M. Notably, PROCEPT BioRobotics's price-to-earnings ratio is -- while Intuitive Surgical's PE ratio is 84.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PROCEPT BioRobotics is 20.84x versus 24.04x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRCT
    PROCEPT BioRobotics
    20.84x -- $58.4M -$21M
    ISRG
    Intuitive Surgical
    24.04x 84.31x $2B $565.1M
  • Which has Higher Returns PRCT or RXST?

    RxSight has a net margin of -35.93% compared to PROCEPT BioRobotics's net margin of -17.95%. PROCEPT BioRobotics's return on equity of -37.42% beat RxSight's return on equity of -14.78%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRCT
    PROCEPT BioRobotics
    63.24% -$0.40 $292.7M
    RXST
    RxSight
    71.42% -$0.16 $277.3M
  • What do Analysts Say About PRCT or RXST?

    PROCEPT BioRobotics has a consensus price target of $102.75, signalling upside risk potential of 26.59%. On the other hand RxSight has an analysts' consensus of $58.00 which suggests that it could grow by 72.26%. Given that RxSight has higher upside potential than PROCEPT BioRobotics, analysts believe RxSight is more attractive than PROCEPT BioRobotics.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRCT
    PROCEPT BioRobotics
    6 2 0
    RXST
    RxSight
    5 2 0
  • Is PRCT or RXST More Risky?

    PROCEPT BioRobotics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison RxSight has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock PRCT or RXST?

    PROCEPT BioRobotics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. RxSight offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PROCEPT BioRobotics pays -- of its earnings as a dividend. RxSight pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRCT or RXST?

    PROCEPT BioRobotics quarterly revenues are $58.4M, which are larger than RxSight quarterly revenues of $35.3M. PROCEPT BioRobotics's net income of -$21M is lower than RxSight's net income of -$6.3M. Notably, PROCEPT BioRobotics's price-to-earnings ratio is -- while RxSight's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PROCEPT BioRobotics is 20.84x versus 9.91x for RxSight. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRCT
    PROCEPT BioRobotics
    20.84x -- $58.4M -$21M
    RXST
    RxSight
    9.91x -- $35.3M -$6.3M
  • Which has Higher Returns PRCT or TFX?

    Teleflex has a net margin of -35.93% compared to PROCEPT BioRobotics's net margin of 14.52%. PROCEPT BioRobotics's return on equity of -37.42% beat Teleflex's return on equity of 5.32%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRCT
    PROCEPT BioRobotics
    63.24% -$0.40 $292.7M
    TFX
    Teleflex
    56.28% $2.36 $6.2B
  • What do Analysts Say About PRCT or TFX?

    PROCEPT BioRobotics has a consensus price target of $102.75, signalling upside risk potential of 26.59%. On the other hand Teleflex has an analysts' consensus of $238.68 which suggests that it could grow by 33.97%. Given that Teleflex has higher upside potential than PROCEPT BioRobotics, analysts believe Teleflex is more attractive than PROCEPT BioRobotics.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRCT
    PROCEPT BioRobotics
    6 2 0
    TFX
    Teleflex
    0 9 0
  • Is PRCT or TFX More Risky?

    PROCEPT BioRobotics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Teleflex has a beta of 1.156, suggesting its more volatile than the S&P 500 by 15.641%.

  • Which is a Better Dividend Stock PRCT or TFX?

    PROCEPT BioRobotics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Teleflex offers a yield of 0.76% to investors and pays a quarterly dividend of $0.34 per share. PROCEPT BioRobotics pays -- of its earnings as a dividend. Teleflex pays out 17.93% of its earnings as a dividend. Teleflex's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios PRCT or TFX?

    PROCEPT BioRobotics quarterly revenues are $58.4M, which are smaller than Teleflex quarterly revenues of $764.4M. PROCEPT BioRobotics's net income of -$21M is lower than Teleflex's net income of $111M. Notably, PROCEPT BioRobotics's price-to-earnings ratio is -- while Teleflex's PE ratio is 35.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PROCEPT BioRobotics is 20.84x versus 2.78x for Teleflex. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRCT
    PROCEPT BioRobotics
    20.84x -- $58.4M -$21M
    TFX
    Teleflex
    2.78x 35.42x $764.4M $111M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

NVIDIA vs Broadcom Stock: Which Is Best?
NVIDIA vs Broadcom Stock: Which Is Best?

If you want to invest in an AI-leading tech company,…

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Will Tyson Foods Stock Bounce Back?
Will Tyson Foods Stock Bounce Back?

Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Buy
55
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
61
QMCO alert for Dec 23

Quantum [QMCO] is up 1.27% over the past day.

Sell
46
NUKK alert for Dec 23

Nukkleus [NUKK] is up 6.7% over the past day.

Sell
1
IIPR alert for Dec 23

Innovative Industrial Properties [IIPR] is down 5.95% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock